Healthcare / BiotechnologyHKSE
$20.76
-0.98 (-4.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $98.1M · quality 73.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
62/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.9B
P/E
11.0x
↓EV/EBITDA
6.8x
↓ROE
13.7%
↑Gross Margin
63.4%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.6%
FCF CAGR
+47.9%
FCF margin
24.2%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $570.1M · net income $217.4M · FCF $137.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $570.1M | $570.1M | $442.2M | $336.8M | $350.8M |
| Net Income | $217.4M | $217.4M | $59.2M | $48.9M | $54.0M |
| EBITDA | $281.3M | $281.3M | $109.7M | $92.0M | $94.8M |
| EPS | 1.63 | 1.63 | 0.47 | 0.34 | 0.43 |
| Gross Margin | 63.4% | 63.4% | 56.5% | 53.5% | 57.3% |
| Operating Margin | 39.4% | 39.4% | 31.7% | 26.3% | 32.9% |
| Net Margin | 38.1% | 38.1% | 13.4% | 14.5% | 15.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.13 | 1.27 | 1.61 |
| Current Ratio | 6.40 | 6.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $137.7M | $137.7M | $98.1M | $32.7M | $42.6M |
| Returns | |||||
| ROE | 13.7% | 13.7% | 18.6% | 19.3% | 26.7% |
| Valuation | |||||
| P/E | 10.98 | 10.98 | — | — | — |
| EV/EBITDA | 6.81 | 6.81 | — | — | — |
| P/B | 1.75 | 1.75 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 28.9% | 28.9% | 31.3% | -4.0% | — |
| EPS Growth | 244.3% | 244.3% | 37.3% | -20.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
4.2%
EPS terminal req.
$1.84
Spread vs growth
240.2%
5Y implied EPS CAGR
6.5%
EPS terminal req.
$2.23
Spread vs growth
237.9%
10Y implied EPS CAGR
8.2%
EPS terminal req.
$3.59
Spread vs growth
236.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.6%
Start / end P/E
65.1x → 12.7x
EPS bridge
0.47 → 1.63
Residual
-196.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.